Fate sees positive B-cell lymphoma data at #ASCO21; ImaginAb secures funding for CD8 imaging trials
Fate Therapeutics revealed some new data at #ASCO21 for their R/R B-cell lymphoma program on Friday.
The San Diego biotech said interim Phase I data for FT516 revealed eight of 11 patients as of the March cutoff date had achieved an objective response, including six who hit levels of complete response. Four of the patients came from the second dose cohort, while the other seven came from the third dose cohort.
“Based on the favorable therapeutic profile of FT516 that continues to emerge and the potential to treat patients on-demand without delay, we plan to initiate multiple indication-specific, dose-expansion cohorts for patients with B-cell lymphomas to broadly assess FT516 in combination with CD20-targeted monoclonal antibody regimens,” Wayne Chu, VP of clinical development, said in a statement.
Patients had received a median of three prior lines of treatment, and a median of two prior lines containing CD20-targeted therapies. Of the 11 patients, eight had aggressive B-cell lymphoma, five were refractory to their most recent prior therapy and four had previously been treated with autologous CD19 CAR-T cell therapy.
The biotech added that no dose-limiting toxicities nor treatment-related serious side effects above Grade 3 were observed. — Max Gelman
ImaginAb secures funding for CD8 imaging trials
A Los Angeles-based biotech focused on radiopharmaceutical imaging and therapy agents announced that it has secured $12.8 million to expand its clinical trials.
ImaginAb secured the money from existing investors Adage Capital and Cycad Group, and were joined by new investors Norgine Ventures and Theravance Respiratory Company. Proceeds will help the company expand its CD8 ImmunoPET clinical trials that are being administered in more than 20 hospitals in North America, Europe and Australia, the company said in a release.
“We are pleased to secure this financing to support our imaging and RPT initiatives. ImaginAb is an innovative leader within the ImmunoPET imaging field and have experienced strong revenue growth over the last 12 months as our technology continues to be embraced by our pharma and biotech partners,” chairman K. Leonard Judson said in a statement.
It will also aid R&D. CD8 is a minibody that binds the CD8 receptor on human T cells, which are the main effector cells involved in anti-tumor responses. Images of these cells can be used to diagnose patients, measure the efficacy of therapies and predict outcomes.
“ImaginAb’s vision is to be the lead in diagnostic and treatment choices, helping patients live better and healthier lives,” CEO Ian Wilson said in a press release. — Josh Sullivan
Magneta reveals stem cell collection and mobilization data
Ahead of the expected exit from Magnenta’s CMO and R&D chief, the biotech revealed new data at #ASCO21 on Friday.
The Cambridge, MA-based stem cell player revealed the Phase II results for their MGTA-145 and plerixafor combo in patients with multiple myeloma. Magenta’s goal of the study was “to mobilize and collect hematopoietic stem cells for autologous stem cell transplant” in such patients, the company said in a statement.
Cumulative data as of the May 12 cutoff date show that all 15 patients treated with the combo met the primary endpoint of sufficient stem cell mobilization and collection. Additionally, 12 of the 15 patients hit the goal in a single day of treatment.
Researchers had been aiming for patients to collect 2 million CD34+ stem cells per kg in up to two days. The median number of stem cells collected was 6.3 million per kg, and all 12 patients that have received transplants saw successful engraftment. — Max Gelman
Surface teams up with Roche to add drug duo to HCC treatment
After collaborating with a division of Merck in March, Surface Oncology will join forces with Roche on an oncology study of SRF388, the company announced Friday.
The investigational IL-27 antibody will be used in combination with Roche’s atezolizumab and bevacizumab in patients with treatment-naïve hepatocellular carcinoma. The combination of atezolizumab and bevacizumab has proven to improve overall survival.
In March, the company unveiled a collaboration deal with Merck’s Keytruda, as a part of a Phase I study of the use of SRF388 to target IL-27 in patients with liver and kidney solid tumors. Surface has identified the tumor types that it believes IL-27 has a role in providing resistance, and it got its first Phase I results back in November 2020.
Surface CMO Alison O’Neill said in a statement:
At Surface, we are committed to identifying and accelerating the delivery to patients of life-changing treatments, whether as a single agent or in scientifically and clinically appropriate combinations. This collaboration leverages Roche’s deep experience in hepatocellular carcinoma and Surface’s commitment to rationally and rapidly develop SRF388, a first-in-class antibody against IL-27, to provide meaningful benefit to patients with liver cancer.